Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
Open Access
- 14 June 2023
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 21 (1) , 1-15
Abstract
Background: The impact of immunosuppressive therapies on the efficacy of vaccines to SARS-CoV-2 is not completely clarified. We analyzed humoral and T cell-mediated response after COVID-19 mRNA vaccine in immunosuppressed patients and patients with common variable immunodeficiency disease (CVID). Patients: We enrolled 38 patients and 11 healthy sex- and age-matched controls (HC). Four patients were affected by CVID and 34 by chronic rheumatic diseases (RDs). All patients with RDs were treated by corticosteroid therapy and/or immunosuppressive treatment and/or biological drugs: 14 patients were treated with abatacept, 10 with rituximab, and 10 with tocilizumab. Methods: Total antibody titer to SARS-CoV-2 spike protein was assessed by electrochemiluminescence immunoassay, CD4 and CD4-CD8 T cell-mediated immune response was analyzed by interferon-γ (IFN-γ) release assay, the production of IFN-γ-inducible (CXCL9 and CXCL10) and innate-immunity chemokines (MCP-1, CXCL8, and CCL5) by cytometric bead array after stimulation with different spike peptides. The expression of CD40L, CD137, IL-2, IFN-γ, and IL-17 on CD4 and CD8 T cells, evaluating their activation status, after SARS-CoV-2 spike peptides stimulation, was analyzed by intracellular flow cytometry staining. Cluster analysis identified cluster 1, namely the “high immunosuppression” cluster, and cluster 2, namely the “low immunosuppression” cluster. Results: After the second dose of vaccine, only abatacept-treated patients, compared to HC, showed a reduced anti-spike antibody response (mean: 432 IU/ml ± 562 vs mean: 1479 IU/ml ± 1051: p = 0.0034), and an impaired T cell response, compared with HC. In particular, we found a significantly reduced release of IFN-γ from CD4 and CD4-CD8 stimulated T cells, compared with HC (p = 0.0016 and p = 0.0078, respectively), reduced production of CXCL10 and CXCL9 from stimulated CD4 (p = 0.0048 and p = 0.001) and CD4-CD8 T cells (p = 0.0079 and p = 0.0006). Multivariable General Linear Model analysis confirmed a relationship between abatacept exposure and impaired production of CXCL9, CXCL10, and IFN-γ from stimulated T cells. Cluster analysis confirms that cluster 1 (including abatacept and half of rituximab treated cases) showed a reduced IFN-γ response, as well as reduced monocyte-derived chemokines All groups of patients demonstrated the ability to generate specific CD4 T activated cells after spike proteins stimulation. After the third dose of vaccine, abatacept-treated patients acquired the ability to produce a strong antibody response, showing an anti-S titer significantly higher compared to that obtained after the second dose (p = 0.0047), and comparable with the anti-S titer of the other groups. Conclusions: Patients treated with abatacept showed an impaired humoral immune response to two doses of COVID-19 vaccine. The third vaccine dose has been demonstrated to be useful to induce a more robust antibody response to balance an impaired T cell-mediated one. All patients, exposed to different immunosuppressive drugs, were able to produce specific CD4-activated T cells, after spike proteins stimulation. Trial registration: Local Ethical Committee NP4187.Keywords
This publication has 52 references indexed in Scilit:
- The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximabVaccine, 2011
- CXCR3 ligands: redundant, collaborative and antagonistic functionsImmunology & Cell Biology, 2011
- Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximabArthritis & Rheumatism, 2009
- CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine productionArthritis Research & Therapy, 2009
- Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adultsVaccine, 2009
- CTLA-4 ligation blocks CD28-dependent T cell activation.Journal of Experimental Medicine, 1996
- New perspectives of C1328-137-mediated T cell costimulationImmunity, 1995
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994
- CTLA-4 is a second receptor for the B cell activation antigen B7.Journal of Experimental Medicine, 1991
- Biochemical characterization of a gamma interferon-inducible cytokine (IP-10).Journal of Experimental Medicine, 1987